{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:45:46Z","timestamp":1790873146216,"version":"4.1.0"},"reference-count":134,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1080\/14740338.2020.1709440","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T18:07:55Z","timestamp":1577210875000},"page":"117-130","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["The safety of ixekizumab in psoriasis drug therapy"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.024"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40753"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.039"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18384"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13927"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15292"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16736"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16426"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13768"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.97"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14052"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171849"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00340-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08360-9"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S100940"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.04.019"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2013.13125"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0152-x"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.009"},{"key":"e_1_3_4_37_1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian E","year":"2017","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.027"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1422591"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.020"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15277"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868"},{"key":"e_1_3_4_43_1","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.15879","article-title":"Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis","volume":"34","author":"Erichsen CY","year":"2020","unstructured":"Erichsen CY, Jensen P, Kofoed K. Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):30\u201338.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_4_44_1","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg A","year":"2020","unstructured":"Egeberg A, Andersen YMF, Halling-Overgaard A-S, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2020;34(1):39\u201346.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16140"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0162-4"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-015-0092-3"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395796"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0102-0"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.63"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1023295"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1132695"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0800-7"},{"key":"e_1_3_4_55_1","first-page":"8","article-title":"A review of guselkumab, an IL-23 inhibitor, for moderate-to-severe plaque psoriasis","volume":"22","author":"Nawas Z","year":"2017","unstructured":"Nawas Z, Hatch M, Ramos E, et al. A review of guselkumab, an IL-23 inhibitor, for moderate-to-severe plaque psoriasis. Skin Therapy Lett. 2017;22:8\u201310.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1242409"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0254-4"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S111107"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S111007"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.09.021"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S92128"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S129792"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0629-2"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1559730"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018799982"},{"key":"e_1_3_4_66_1","volume-title":"Ixekizumab. StatPearls","author":"Preuss CV","year":"2019","unstructured":"Preuss CV, Quick J. Ixekizumab. StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. cited 2019 May 5. Available from http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431088\/"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.08.046"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.048"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.047"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16050"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.032"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14581"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1249820"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14237"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14033"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14252"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1473551"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13990"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-016-0246-9"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.06094-7"},{"key":"e_1_3_4_82_1","first-page":"e12886","article-title":"From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management","author":"Damiani G","year":"2019","unstructured":"Damiani G, Conic RRZ, Pigatto PDM, et al. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019;32(3):e12886.","journal-title":"Dermatol Ther"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00490-2"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15100"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418814229"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.003"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3200"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01907-y"},{"key":"e_1_3_4_89_1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17580","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience","volume":"180","author":"Conti A","year":"2019","unstructured":"Conti A, Peccerillo F, Amerio P, et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol. 2019;180(6):1547\u20131548.","journal-title":"Br J Dermatol"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1506081"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15288"},{"key":"e_1_3_4_92_1","article-title":"Efficacy and safety of ixekizumab in a real-life practice: a retrospective bicentric study","volume":"110","author":"Magdaleno-Tapial J","year":"2019","unstructured":"Magdaleno-Tapial J, Carmena-Ram\u00f3n R, Valenzuela-O\u00f1ate C, et al. Efficacy and safety of ixekizumab in a real-life practice: a retrospective bicentric study. Actas Dermosifiliogr. 2019;110(7):585\u2013589.","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15242"},{"key":"e_1_3_4_95_1","first-page":"200","article-title":"Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials","volume":"17","author":"Shear NH","year":"2018","unstructured":"Shear NH, Paul C, Blauvelt A, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol. 2018;17:200\u2013206.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_96_1","first-page":"695","article-title":"Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis","volume":"16","author":"Henderson Berg M-H","year":"2017","unstructured":"Henderson Berg M-H, Carrasco D. Injection site reactions to biologic agents used in psoriasis and psoriatic arthritis. J Drugs Dermatol. 2017;16:695\u2013698.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.727796"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_786_17"},{"key":"e_1_3_4_99_1","first-page":"893","article-title":"Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein","volume":"137","author":"Zeltser R","year":"2001","unstructured":"Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein. Arch Dermatol. 2001;137:893\u2013899.","journal-title":"Arch Dermatol"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15156"},{"key":"e_1_3_4_101_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3254043589","article-title":"Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis","volume":"25","author":"Mart\u00ednez-Dom\u00e9nech \u00c1","year":"2019","unstructured":"Mart\u00ednez-Dom\u00e9nech \u00c1, Garc\u00eda-Legaz-Mart\u00ednez M, Magdaleno-Tapial J, et al. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis. Dermatol Online J. 2019;25(4).","journal-title":"Dermatol Online J"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12852"},{"key":"e_1_3_4_103_1","unstructured":"taltz-epar-product-information_en.pdf [Internet]. cited 2019 Oct 27. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf."},{"key":"e_1_3_4_104_1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17604","article-title":"Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis","volume":"181","author":"Romiti R","year":"2019","unstructured":"Romiti R, Valenzuela F, Chouela EN, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019;181(1):202\u2013203.","journal-title":"Br J Dermatol"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3631"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1228872"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479163"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16073"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_4_112_1","unstructured":"761032lbl.pdf [Internet]. cited 2019 Oct 29. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf."},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17084"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S165605"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.02.002"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3056"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.026"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1736"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.024"},{"key":"e_1_3_4_126_1","unstructured":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis - No Study Results Posted - ClinicalTrials.gov [Internet]. cited 2019 Oct 20. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03573323."},{"key":"e_1_3_4_127_1","unstructured":"Canada EL. New head-to-head data show TALTZ\u00ae (ixekizumab) Superiority versus TREMFYA\u00ae (guselkumab) in people with moderate to severe plaque psoriasis [Internet]. GlobeNewswire News Room. 2019 cited 2019 Dec 16. Available from: http:\/\/www.globenewswire.com\/news-release\/2019\/10\/10\/1928383\/0\/en\/New-Head-to-Head-Data-Show-TALTZ-ixekizumab-Superiority-versus-TREMFYA-guselkumab-in-People-with-Moderate-to-Severe-Plaque-Psoriasis.html."},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1540931"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23738"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.016"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12909"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208025"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2018.07.005"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i33.3681"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-1067-0"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.034"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2020.1709440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:04:56Z","timestamp":1770933896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2020.1709440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":134,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1080\/14740338.2020.1709440"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2020.1709440","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}